A Phase II Trial of LM103 in Advanced Melanoma

A total of 92 subjects with advanced melanoma who met the inclusion criteria will be randomly assigned in a 1:1 ratio to the experimental group and the control group in this phase II trial. The study will be followed up until 24 months after treatment.

Trial Details

NCT ID
NCT07310784
Phase
PHASE2
Sponsor
Suzhou BlueHorse Therapeutics Co., Ltd.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • LM103 TILs Injection
  • Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Nanning, Guangxi, China|22.81667,108.31667
  • Nanning, Guangxi, China|22.81667,108.31667

Key Eligibility Criteria

  • At the date of signing Informed Consent Form (ICF), 18 \~75 years old, male or female;
  • Expected survival time \>3 months;
  • ECOG performance status 0-1;
  • Patients with unresectable recurrent/metastatic melanoma (excluding uveal melanoma) who have failed at least two lines of standard treatment: • Pat…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →